CAPTIS
Financiado
An Embolic Protection Device for stroke prevention during heart valve replacemen...
Aortic stenosis (AS) is the most common and most severe heart valve disease, affecting 20 million people worldwide. For
patients with severe AS, the most common treatment is valve replacement through Transcatheter Aortic Valve Imp...
Aortic stenosis (AS) is the most common and most severe heart valve disease, affecting 20 million people worldwide. For
patients with severe AS, the most common treatment is valve replacement through Transcatheter Aortic Valve Implantation
(TAVI). The procedure is very risky, since embolic debris are released to the blood stream and may reach the brain and
other organs, reducing or blocking the blood flow. Strikingly, embolic debris cause new ischemic brain lesions in 70% of
patients post TAVI, major disabling strokes in 9%, and kidney dysfunction 12.3% of cases. Embolic Protection Devices
(EPDs) are being developed to reduce the risk posed by embolic debris during TAVI. To date, only one EPD has been
commercialised for use in TAVI procedure. Unfortunately, the device is poorly effective since it can only provide partial
cerebral protection, interferes with the TAVI delivery system, and requires secondary artery access to the TAVI system, thus
increasing procedure time and posing the patient at a higher risk of post-operative side effects.
Filterlex developed the CAPTIS® system, an innovative intra-aortic Embolic Protection Device (EPD) for deflecting,
capturing and removing embolic particles during TAVI procedure. Easily positioned, deployed and retrieved through the
same TAVI artery access, this revolutionary EPD provides full-body protection by ensuring the best performance in capturing
and safely removing the embolic debris released during TAVI. In this way, CAPTIS strongly reduces the risk of stroke and
ischemia to other vital organs.
The key objectives of the project are to validate safety and efficacy of the CAPTIS system through a First-In-Human clinical
trial and multi-site clinical trial, and to obtain CE mark certification for commercialisation in Europe.
ver más
Duración del proyecto: 24 meses
Fecha Inicio: 2019-08-30
Fecha Fin: 2021-08-31
Fecha Fin: 2021-08-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2021-08-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020:
SME instrument
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
3M€
Líder del proyecto
FILTERLEX MEDICAL LTD
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
599.49K€ |
Participante